Physician profile
Steven Millen
NPI 1710182209
$2,702.37
in general payments reported to CMS, 2019-2025
30 companies · $546 in 2025
The $546 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $296 · 2022: $431 · 2023: $726 · 2024: $703 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,849 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,849.34 |
| Education | $126.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $622.92 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $240.60 | 2021-2025 | |
| Novo Nordisk INC | $216.98 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.60 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $186.88 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $141.40 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $116.21 | 2022-2024 | Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $106.50 | 2024 | |
| Janssen Pharmaceuticals, INC | $103.10 | 2023-2024 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $95.86 | 2021-2023 | Rexulti |
| Gilead Sciences, INC. | $65.11 | 2025 | |
| Lundbeck LLC | $63.10 | 2023-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $60.80 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.36 | 2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $58.54 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $55.03 | 2021-2022 | |
| Corcept Therapeutics | $54.66 | 2024-2025 | Korlym |
| Exact Sciences Corporation | $40.65 | 2023-2024 | Cologuard Collection Kit |
| Viatris Specialty LLC | $32.76 | 2025 | Yupelri |
| Abbott Laboratories | $23.98 | 2023 | Freestyle Libre 2 |
| Inspire Medical Systems, INC. | $20.34 | 2025 | Inspire |
| Almatica Pharma LLC | $19.47 | 2021 | |
| Grifols USA, LLC | $18.58 | 2024 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $17.46 | 2022 | |
| Bausch Health US, LLC | $17.34 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.97 | 2025 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $15.14 | 2024 | Uptravi, Opsumit |
| Pfizer INC. | $13.47 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.29 | 2025 | Voquezna |
| Uswm, LLC | $12.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Millen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.